Targeting neuroblastoma cells with a new T cell therapy
Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma models
This study is exploring a new way to help kids with neuroblastoma by using a special treatment that helps their immune system find and attack the cancer cells more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10946469 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating neuroblastoma, a challenging childhood cancer, by using a multispecific T cell engager that targets specific proteins on cancer cells. The therapy aims to redirect the body's immune T cells to recognize and destroy neuroblastoma cells by binding to ROR1, PD-L1, and CD3. By leveraging the immune system's ability to fight cancer, this approach hopes to improve outcomes for patients with recurrent neuroblastoma. The study will assess the effectiveness and safety of this treatment in preclinical models before potential clinical application.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with neuroblastoma, particularly those with recurrent or resistant forms of the disease.
Not a fit: Patients with neuroblastoma who do not express the targeted proteins (ROR1 and PD-L1) may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new immunotherapy option for children with neuroblastoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar T cell therapies, indicating potential for success with this novel approach.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Olson, James M — Seattle Children's Hospital
- Study coordinator: Olson, James M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.